<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Choice of adjuvant systemic therapy for patients with high-risk muscle-invasive urothelial carcinoma of the bladder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Choice of adjuvant systemic therapy for patients with high-risk muscle-invasive urothelial carcinoma of the bladder</h1>
<div class="graphic"><div class="figure"><div class="ttl">Choice of adjuvant systemic therapy for patients with high-risk muscle-invasive urothelial carcinoma of the bladder</div><div class="cntnt"><img src="data:png;base64,iVBORw0KGgoAAAANSUhEUgAAAVsAAAGWBAMAAAAklz20AAAACXBIWXMAAAPoAAAD6AG1e1JrAAAAKlBMVEX///8AAACGhoZERERgYGC7u7siIiKdnZ3d3d0zMzMRERHMzMzu7u7CwsLjzaMiAAAZ/UlEQVR42uycy1MbVxaHbz/0MDBVOkKtB3jRsog84E1LM2VXJrNoBcUVTzbdFFCO44XEGEMZFi0qkZ9TJWHGZZwsaI+r8CQs0IKRU7AQSWoerGTHQw0ki5n/aM7tlmSMQQjUUixXn7KBq7739KdfH917uw8HQmyzzTbbbLPNNmoMtMpag9syHWxcG9fGPcSrsOdlZf8rx7HRVuKyKTJh4AmvUKu46gFDOPGNt0XiezssDl9oMe5x1D0Sl6SVlqubADEEGiGqmvlM9zFXn6BKIKiugncR5AzId0BMhMqEh0AGu/FQ3GC/0X0JmIcZFrwQCIdK5+F834LEiYuXWqougJcZecaJXjaVDqgiM7JEmNso4TAGA0qZdK8T1+k4YVdOUV0vUXWjOTLlnMN+ylZpYFMh8e5+XvqNS3D+OpjPtSF2R2VOFFwpVJcwlxPLzLd4bApxHfoHaQjchuCnvT8AyIQt+ClukpBI1o39lAz4sxgMrpQjFXd4ODE+0OKZwcAdmd2u4SokytyWkKmbftSSiDbhChL+wxXsn9eiFXV3H+M3Rtsqkaq6Bu74ejtwr+r+Gu4IBJirfy2Tv4cwGGBmEYJhfzDmLyUwaDm47jK+rbIbLAR4jF0fC/0ZGrsG7impPfPutna8kXsniD22q7QFF3qPOTJTPvDlQXsRtnFtXBu33biddSd8LPN01kMJG9fGtXFtXBv3LVzc2vGemM66BDaujWvjdtrkbJtttr2DVk2ONGesZAVKv2vPrBg5BHe40fOGQT7s7bFS5rX2iRJ0zHWX55jq1sONuicaVfdkuENnPYsgEhICLX4+4igUuUiKcLrPTf95XYBfYbTXKeYfiLufQwCP5KmCh+GSpKpmlFjvv4UAYa+HyolQOdb7HwiVw3ABeMl5c5VdBh8eeQnBk+DOeT3J7jVCvOzq+7lIl3jnx6eEcJK6ID/6Qd5SSOalxCgRxJ1PRWlKSlLn66nbXaRprdmd97yo5/Tu3MqpM7M7IsnfFVhJRdx7xS6NZF5M72onU/de2jNFLuC1cQTjJJLPMfdFmmTIPwDIatxNHR5oJu5Xa8tGSio/Xz92VcKMyuxHHnr5nZ8DJGX2kxjcTJm4WiTr0mEefzgZrpZBdXGowKYQt0sc+tHEXZAJL2+Oi5kFeVOJcHI4d3HDSEnl55fqqGvmiWa33zNx51YIO7s9sPT8bj8vqWzqipafcIoZihs4Ga7TjF3wK4hLY9fEfajDQ93LQvrLtK5EHKDn8iIH1/HIlwX5CFwauyaulgANG4W0lghJqjv9tcZvoE+Kmwg2M6PVvTZJS+bvIQvXgnq4mTUrzpD32itux9j+ZaeJRT5yRNt6XIfHMlzVxl2ED3GJD/tLfkiEcLfghAmzHbiW9pdCcEtwnG7ME+42oukVFmaYtA+WcFJP+yvt7EX8ogfyilpuFneYLvF311nZy0/nR+WtMU+l7SPEKeKOIsnLjXniJRL9qrhVGmDEiw8F3JCo1TY6mGDEIV5ufh6foovQTYAU7kWYcY37wlNt9yRAxh3FlXyuMU9ODS/+VAb8uNcgAm5I1Fr7JfgYRf3zsyCxQF3JeXedbh4k3KNsjp2utl2nT8m4o+CekIbVRbytEjFw6a/DlKvtTPkJo0TJ+7IVsYsLOe6oKO5l3dujT1Tabt0v447C1egWCmMX8VgqJOJi7O74q+1FuMbAJMkoLZ6TBYvutcxbkwhpPe4jzSpcd9FekzvQ+IBlrhKajduRuN0AYvh3PpLoaxp3E7xsb0HmodBKdTdXw2LhO58F6nb3sd6u/rDcQnXdCTgdFvXvvM3jLgC88J7qD4stxOW9XSYu1zRuQiyYuLEWxm7ha4pbin3bNO5WyMDl+vQ2zAy22fZOmDUpCot8pQEisIYzD4Dk/mNzp0BfZ2DGGl+HGa3lGTQ97fQ2eQqV8KWkRb4Ocq/PGLiVUzwZdkOoTByFIhsPmokKr1sHhZbMHHWDGq/6Gtjvq5b0aNBXHVzUAk+RmeZBZhROGqbFG6RLvPNispKo2BqVmBGzZKae5R8GK74cz/b7qiU9GvRV7+JFDUWihiJ5gA9ioJF8jqF5CJqo0LisxowCHHXHzZ2RK76ypf2+qkmPRn3Vw32C/xdzQ5WwGuaXnlNFhl5IlUTF5qi8ObJypCPHjZLpi1sh+33Vkh4N+qqDC0/xFC9hsnoKRyGtGbErVRIV3u60rtCSmSPsLxVfqGpun69a0qNRX3VnBUusZ806X23AZZfagWvbL2FxyzxxYksABXVv8MWbWCyZMY/DswdXaP2nril198BarW60sMLB7/8FspD2q05x94s03qXx4GU+030szORhBY+F/aUG5oYb9DcYftJ9zDhMeiZ6iuN0gk2AKBge/gmhnwyXzeH+PBH9+fGgGQxsKtql3aHFnnFacbtVGiDuwCDpXmcbWDfZ2e0zsztnlsxgiLKpomuVsNMYDBUP+TnTZTMWIb9NkoGFkEZxe9aWjUUpibF7ObGcAf/3EFgI0URFA7gSl5TZjxPLBu7up7cAgoSnNbyGh5kY3DJcNofrLqLAhE0JalklFze6NFNyWnG7VSKXegKEnVlvaKGQHs3Nboskyoyddnj4G+WiKTl+1KgHYwNBXTZlYZAxdsOgCTt+XPBFRxrf/k7fBK24ZcF3xR/AY+FGNlHYm8R6X9BCXX3S4/aScbwmPfrfRMHw8FEhPWe4bDIYLFuGpTasBx2Ga5ttttn2Tj7Bs86Vx8btaNxfaQz5U+fguvsSfwh2UDCkG9qMvzW4GWjiIVb7cbugr5NmBr7JDX+7JzLwdBRuTOoo3P/9t6Nw2c5ahMkvggvtN08TuJ63QEwb18Z9+3HDIFmBW3kGxijVp+5vrlmvPdh/7ZmZ+dhrf5rioLRFNwjN4yYgEDEo4zVc18arHsIrXEapQByJW+u5d1M0Ywlu8k11D3hOGN+LdBJceqKwRbiciGEVZ/QA/uAvkTzMwTdMVkZJVmmOgxaGOmEmAfmxUF/JSK3U0idGPCb6cKwjHeDSvelnLHyDPc125JpRL+oUdzV6IquC4VyARVxxiDtH8xmstFkapmUX0RwRBo3C0DitwVCYMYH7GIL0yX8lffKJgOqy04QRaYKFkzLKBB2rVNpPab2ovPmPVJZ8v2IJrqHu2RTFVdT7Z+lNGCtlyTi9nFQQmkFxBONGDQYz5uFlI7VSTZ9M4UCCrzFKNg9wX1RJ3BhbbRv1osy9tWWSJdbhnqN/UZRRoqiuEY6GQqa6NIPCpuK0BkOr4rqL1fQJ/VOkhrpKtkvD0EdcOlarto160UxucNX83Fo1MyT8iAuTNIhpMGD8UVwOYzcMGi0MXYRrPMaugYt9aumTRAgRYn2I50j7DVwciz0rbVovCl7yXLRK3epEIx/eq7mELZ1trpStXdVioVwrcR/be4aOwHUdlN52eA7OpZlLWC25/0BrO65TU//P3vn9NpFdcfxkPP6RmEo+icc/klQaY2o26T44JpSl7cM4CbtQ9sGzUtFCX2y0KKjwYGdZV0R9sNMV2rB9wCwVWykPJGKVrZKHBFi23SeTdldq1Id967/Te87Y+QUxnmDPBHpHiHgMw3x8OL73zLnnfK/hDW+72R7cZo3Fzul5C9e76jjuTTCH1f1xd0cDe3DhvuO4E2BmNu+JCV78KmESH0AA498TrogYoh9lWKm8pzypF0Q0QeUTWfGn86jfpUuPOY57CszysXExwdMcr1tdpNVPCFfMaWFyBu7bFIb36Vw+sdD7M9KYOOYxVuBjN3BvDY2LCd6a4wd1CI4h41LEQLjct+l5O8vznWcK8QxpTMzO3H/gAq5whrm0sC7wHA/BGBVBNK1LuEXu2/QcH+41uHxiQfjuVFDr+3rUcMEZxFetAuNighe//FgSJvQuFhiXIgbIsFK5wH2rFjG4fCIrbC98V00/K7rwVfMdYOwE9wYy/ytUQbkwTciYQeK+qbi3+g8jropYLONflMVw3V+L6PtkmF70mLHzWePDl5dbvjpuDXV6VvNHYaJUnDdMfWcaZ8IG7s0vrfYYR3BVneCCw3xDbzyyRmIcBYyxIBerdIhQLT64lsBvqCL2HziFsULkCUbF43EC1wBGTgK8dF7uEC7ix2LQvwyB2GUv5sE7pJ5nMY6MwoJcpNKRE6Ga5jmvAVfEjrBhfbrmF7jUdsmdrd6vHbOu0bSuP0/aLNMkxiGCBhbkIh2J31Gopr6Xt9o0KL3DUh2EmwrXLetye4wDXzXhu/2W75Z0hXB7z69wBKmwIBerdFCoprJ1+dEiHyWpjqg3Nm9Yb9380rPg3Mgwiie3RgYvxiskxgEZYEEuwv0thWrkp99QRWwCi9mYCNOysbG/vb9odWx9aLXHOD/uers1g0hcGTNI3DcG106Xy2bFCdwEnt0OwpKwe7mqFe7oAIyFtyebRu5h3/alzkzCyrXAyf1jxn1w1VNAcZxyvSk6RLinnIgZaBLN/IK39TuL4aSnFlbSp9GYp+aNBD6m9bbCllpa8QK+VSOL3nhY7xXxhi4+jlKI16ICN7DKq2s91hJct3B7hMedrljb+glnYPHUE94YvRHUwFpv8+kNtbT8krDjbaLpifYsDnh0jwHK1ao+KXAVnVfXaAnO6LJ1wdrWj3BJPDUTiIk3KD7zHEe8TtGXFYJdjYGPywqFdftyt2+wdUkrVuD2rfH6T2NNq1tfNeVK4GQGrG39RrZxKVS3rAsslGb9xtZt+K4w8wz5bhP3JjiBC1k8mwFrW7/vwlu486Tby76LZ0X0xWppAveS8F0ReokwLhqo9fPIYOEiLjmD26HjyDCAE+OunIQlrsR1GLe95j/NXdxRvL8XV98/46W5iMsR2ZWtdFETN5XeP+PlNi7FDKwpq+CAl1JgMHrWyniZtRXxBinHZyhdFqfQ7AnG7KjYdh63mkuEWVN2PZfkFJgv1sh4mTla0yTcK5QuG1IpNNNAxGVtq9h2xbpTrClbhqSViiHrUsbLhCnxxi0KIjhdpnBoBhQ5tKti24WIbJlwS/V762uTVgpM+C5nvAQuLWgaibk0p8t636PEGOG2rWLbnZGBNWVV/IKbwmlkYDMLXFrTxNpcmtJlGP+ME2MC16+5h9vmsTMZdaCeavdwD6RiK2MGiStxnzv21KC/UJAp4wqupz+g7RmfTP/qdqaL3jRfNIY5j0uTsKfw2XOD/s5xdQ+um9Zl3Ml3NA/+mpIKj9IXMJQqLJhVLOWygz5L+R+NZmxGZWUTVgJNfEKq1/0nPuBlSwdxz/Rrqf/cBYgKQy55Q6k/L5tKuueDq8DK/ym2LsdmdG4olEA7R0EvVUObdYg6bF0jq01ReJsKb7wTo6LCaZP1+YGrzsuWM1Bs9oTOFUrxTDNuGS4ogzovWzr4VTOqGlXsA/TNpJeUJq6wLiv/l5U7zdiMzxmXdywi61L1WV/RWVyVfffIYnwjXYo0cXNjg6T8nysHF41GbMbnjPs00vBdE5vLlu6Mu0q+rcuDB2h07wJuYjDXztUm7QclJ2GJK3EPiLvrEWznitoLigbs97p3ISLLbHNu4YoP8Twu9Q0mDN/RO8GhKJRAiTqBuycis2Fd+qujy763L/fqhLt5wvGI7AIebTYGivBA/KC9bnz65gzFafNoiEhMFQFYZE2831/FIqRGf9AvpeqEO9tGWqfDEdkScGNgyvNzsvY5D9Vs3X6UT3GcNhVYEZFYqsIiiKrx3QfCuqnNd3VVo3Z5yLSxMt/ZiCwQY9xc2XM8D9zLRwuUf/zqvkJxWgGjvDbop6ZBX9EzQ7gK6sJNhHUD7ei5dDgiW2riCutyL5+wIsC7qwrFaVMipAmwdYHWK9fZulBo4Cp3jiw7hmtFZHCJfVfgCt99THs/Ch/FSlVX0qW48N2YwPXQw4NBvqswbqmB69Pb2IVRzmoSV+LaSBnsyUlYBepJB3ETVM+w/aAQ6cFqi2JRbXcqKgn7Nzx2BZcqnTK7woOWS2d7cK0CdQdxuRbHh9caCZkmrnjMpa0VZgHWN+jl9GK/igu82zRXRRnJBEbEJBfjDkJr8a317gudwaVKJ5IJaCRkmrjra5MkA/Ds26vH+KWYNUbqd4FX1bgqKpUzLa+nDkJr8a317gsdtO6/MNxIyDRxy3CBwpbekRsT/NJb+1WWxL00f75ZFcW4VgehjxffWu++0CHfpUqnUv1eIyGz07oCV3nYt9J4OTVC/9UC16qKErjiPGN1EFqLbwtOjAxU6TSPHzUSMs2RgXxXp9osJc8vPXhNxSjjWlVRSfh3ROBaHYTW4lvr3RfkrCZxJa7ElbivD+5rpqV34EOqG0tciStxJa7EPci0F3IVN9T9m0tciStx3YnXJa7E/T/DHYH1NXtXJAyf7hruD/pdm1eMLruI6126Po/GrI1iMSptSMTXXPLdbG4qsGKnPje1+S4p+bqEa1JX9sWB9q2VUvB43pt3DZfW+1WjfVwouGrdeYyNRWxYF0ou+q6cJiSuxJW48llN4rY6PodQsGLngv9CyP9jd2/R4nh2KjpWt3NB9WF4sdLdW7Q4VLS57ZsP7W67bfsWLY4g4pCtC/yI0S7fotUxhjajwUV80O1btDhKdjdYzLaz3/ir3aLF0Wd3g8Ue7PotWhyKXfFdz0DXb9HiCNjt8PrJT7t+i1bHj3Yv0Lt/i9fg6EKRQkerHLoaFIde9Z+UuBL3TcdtVS++uz9tVypyj+anE7h+CjSTAe15jAYn/0g2P5HbuJ5f1p+z7i6MBu4hsW71aVHBgao2CdOzMFLFBbO2ksUKzOOZ0Cwe/X38+9CWoKm44jRX8s+Semmghs7jjijp9VwSCHezuAyBqJkbJ6tNCrNmwJI7bwqaforGeHBInGZANW4/Sbtg3QLGymDhKqfyjzFqkgoVwLTAvTjwKO05E9oSNK2QM1Al/8WBp4jlovO43mFLW0FLeZcDEf3cEcYtWtYFdSJ9+5PQlqAp4fpj4hTUKeqyXHccVzVgVsUvQLsVX4bf1C9FCFdt+O5Y5BGGvaEtQdMKPVTp4nQs8vcafl6o5dwZdyG4z4OoLTks53AL6dcKV8YM3cLd2zRtR97cdVwlLXE7h5vAxyIYyMY3SLHcu7hcxUnrPEO9ffHIt6uk3XNYcElwO23OLfQeJcXyPn12I904v0K9fUOqMd323msO4JKcuV79FHGCNLWrlZ65dPOce/uUfLIMh8u6enVuwZIA79NHN+40z7m3r9fYvHvIfFcEA1mcIVzhu8HFycY59fZhvKKsHq6R4SXPae0PFIcCt1SXk7DElbgSV+JKXInrLq6ZPuS4Vna0qWB7LnYIcP+E0xbZzsyt9gLcI1/dPQS4f60n1mAf8Z5duEp+9hA8TQyDqsfxDxgl1dSeWlShug3NrK2IF5lqruwtYEA8a54An75ZdP9ZjZKQ/cqDDOdNe/QUJUsFbm58PQeE26ebtHHWCTArLyshfhXcYzasq3ljGVb8JYndwvuEC1PiiZJwqxXT2jgrixizgWv+r73z+U0iiOL4Y3+w0HLo4EKX1sOSrVSaHihVD8bDEmpqogf20jNgImo8QGMwUQ9gE5PGS6nRNLEH66+1kUPRpAdPqNFE4h/lvNmKrW10NRYWnTlw2EnIJ483s2/mPb7vV2F/d7Cuc/dNd757hfpuRMjvWDdHIW0HF63rK58a0uMS/apZt78lfjRqiFvcPbdXUHIfbrWWdr8zkGiu4vhurtpB9SPERd8VyEOFNFCX7ndw5U19n3X3nvh+xA2hYp/rfTcCf2V8w5Xm83SB+sPoSlvWJ6bpjbVBdP2Kk4+FFWzvmoWSVXhG9AoxExvr7q17CLid28+HsF0ZxRXNOUfTG61L1684bQ8tXvt8jOHmLiqYVUJpRNe+ewgxQ4WodIEyXPml5mh6M1yYE3WjynqtIC6kZSerdML1znAYuGmwOnqcLVS4lHI0vbu49SLL1SVkm+GiIFTA7mdEFhgH/yRpoFr3Q6jkHE1vBX0XcaUma018N+bgxqNavFsk19cA8slAxbuZtUPE9eVDL97loKioEMr8iTR47+JdQrbAN6pEJVM+Kp5uB9flFc/jzgZPKU3JrG+XW21vH34Y7lQ1AXYnlxRSCzAAuNfDCZioYr1Aq+b9o6XvVjMBrVWsFwiuedt3GW4ZEhDUaKx4MzAzpnsdl1+LcFyOy3FdzEc8jesnau0nuLIK1nwT6lvxMlTJg76/hP3lpWs/wyXtjGlDMvQ0pYzuqC73FxdskZz54HRlgGUSkVj1Jn2wQM8t8pHpTdOg4fBLTdI9EOJQ3HTiy6rVHn4lnCNaFiLJ9io9aVttsJXHII8Ws2brY1PU02LZG7j2HEwIY5Os/0IJIhmi4l3O2HG8G5O1whszOGHWSVQyvbDUykt5vJ8YHseuDDA3TK3LtA6GNTxWy5ohmsLVXBI6N8J99t2dnaFNfdciJjtHb8eo72L1Jn2wQM0tayCaoSgUQTKnyEn+muC4HJfjDgruD//+OKBU2uoTbihDzu+KaJwmF8Zent24xnfcbk1qD1/C4lpgfp9h3Vm3+7iHuHh1gzEYpjeWyVmNqE6SwxIuxdrY6kJsqEKqGNBQjEouhA2BjOO0QtQ6yeoxzLz1ELcCM6MsBruojGQdZ2BJDku43FnEVhei2XqNuJihGdLBwHsUOg1QeU+dIYxNJXtr3RKLwdLySInhOkkOS0j5r2OrC1H3LSIuilHVa2AIhQs4rTQIltBGlHxPl1rwEdgsBqO4aN0kOEkOxF3EVheiXrmTOiFoNMZh1gWwcdpPH6/0Hhd3BhaDUVz8/8xb1UlyIG4ZW12IJCykrBgTo5I3wkaHrLNpUri3ke057i/HAXWxhoffagOGy2MGjstx/xvcAZOT4IMPPvjgg49/YXwFWyvdmNPs1CEAAAAASUVORK5CYII="/></div><div class="graphic_lgnd">Management is complex for patients with high-risk muscle-invasive urothelial carcinoma of the bladder at cystectomy. The role of adjuvant chemotherapy in these patients has not been established in fully accrued, adequately powered randomized trials. Neoadjuvant chemotherapy followed by cystectomy remains the preferred approach for these patients. However, some clinicians and patients opt for initial treatment with definitive surgery, reserving the option of adjuvant treatment for those at high risk for recurrence based on pathologic staging. Enrollment in clinical trials is encouraged, where available.</div><div class="graphic_footnotes">ECOG: Eastern Cooperative Oncology Group; NYHA: New York Heart Association; MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin.<br/>* High-risk disease at cystectomy is defined as <strong>either</strong> no prior neoadjuvant cisplatin-based chemotherapy with pathologic (p) T3-T4a and/or node-positive disease; <strong>or</strong> prior neoadjuvant cisplatin-based chemotherapy with pathologic (yp) T2-T4a and/or node-positive disease.<br/>¶ For further details on eligibility for cisplatin-based chemotherapy, refer to UpToDate content on adjuvant therapy for muscle-invasive urothelial carcinoma of the bladder.<br/>Δ Any of these regimens are appropriate for most patients. Some clinicians prefer gemcitabine plus cisplatin over MVAC regimens due to a better toxicity profile. However, others prefer MVAC regimens for fit patients, extrapolating from data suggesting a survival benefit for MVAC in the neoadjuvant setting. Since the use of adjuvant chemotherapy is controversial, patients may alternatively choose observation or clinical trial enrollment. For patients who choose adjuvant systemic therapy, we initiate treatment as soon as surgical recovery permits, typically around six to eight weeks postoperatively, and no later than three months after radical cystectomy.<br/><font class="lozenge">◊</font> Patients who are ineligible for or do not meet indications for adjuvant immunotherapy may be offered observation after cystectomy or clinical trials. We do not suggest the use of adjuvant chemotherapy as data are limited for this approach.</div><div id="graphicVersion">Graphic 131930 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
